Article

How to manage varying demands of hyperopic LASIK

New Orleans-Surgeons need to understand that hyperopic LASIK is profoundly different from myopic LASIK, said George O. Waring III, MD. It is especially important to convey this message to patients who typically may be imbued with the notion

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
(Image credit: AdobeStock/Sam Efendi) Analyzing FLIO data from the AI-READI project with Aaron Y. Lee, MD, MSCI
June 17th 2025

Analyzing FLIO data from the AI-READI project with Aaron Y. Lee, MD, MSCI

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease
June 17th 2025

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA
June 16th 2025

Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA

Retinal imaging study suggests new biomarkers for early diabetic retinopathy detection
June 15th 2025

Retinal imaging study suggests new biomarkers for early diabetic retinopathy detection

© 2025 MJH Life Sciences

All rights reserved.